Comparison of efficacy of moxidectin and ivermectin in the treatment of Strongyloides fulleborni infection in rhesus macaques

Background  Strongyloides infection may result in clinical disease or confound experimental protocols that utilize non‐human primates. There is presently a Strongyloides fulleborni infection rate of approximately 27% in the Tulane National Primate Research Center's breeding colonies despite the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical primatology 2006-06, Vol.35 (3), p.172-176
Main Authors: Dufour, Jason P., Cogswell, Frank B., Phillippi-Falkenstein, Kathrine M., Bohm, Rudolf P.
Format: Article
Language:English
Subjects:
Administration, Topical
Animals
anthelmintic
diarrhea
Feces - parasitology
Female
Injections, Intramuscular
Ivermectin - pharmacology
Macaca mulatta
Macrolides - pharmacology
Male
Monkey Diseases - drug therapy
Monkey Diseases - parasitology
non-human primate
parasite
Parasite Egg Count - veterinary
Specific Pathogen-Free Organisms
Strongyloides - growth & development
Strongyloidiasis - drug therapy
Strongyloidiasis - parasitology
Strongyloidiasis - veterinary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background  Strongyloides infection may result in clinical disease or confound experimental protocols that utilize non‐human primates. There is presently a Strongyloides fulleborni infection rate of approximately 27% in the Tulane National Primate Research Center's breeding colonies despite the routine therapeutic and prophylactic use of ivermectin. Methods  A study was conducted to determine if moxidectin treatment offers advantages to the intestinal parasite control program. A total of 150 rhesus macaques (Macaca mulatta) that were removed from the breeding colonies due to illness were selected for the study. The animals were randomly assigned to treatment groups with 75 receiving ivermectin and 75 receiving moxidectin. Egg counts were performed on fecal samples collected pre‐ and post‐treatment. Results  Both treatments resulted in decreases in the number of eggs/g in the post‐treatment sample as compared with the pre‐treatment sample; however, no significant difference was found between treatment groups. Conclusions  With the data demonstrating a similar efficacy in both ivermectin and moxidectin treated macaques, the benefit of moxidectin treatment relates to biosafety and topical application.
ISSN:0047-2565
1600-0684
DOI:10.1111/j.1600-0684.2006.00154.x